Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? (Q37260299)

19 August 2017

1 reference

title

Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? (English)

1 reference

19 August 2017

0 references

1 reference

F J T Staal

1

1 reference

19 August 2017

K Pike-Overzet

series ordinal

2

1 reference

19 August 2017

Y Y Ng

series ordinal

3

1 reference

19 August 2017

J J M van Dongen

series ordinal

4

1 reference

19 August 2017

language of work or name

1 reference

4 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

22

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1849-1852

1 reference

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Chance or necessity? Insertional mutagenesis in gene therapy and its consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Gene therapy for severe combined immunodeficiency: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Gene therapy for severe combined immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Side effects of retroviral gene transfer into hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Insertional mutagenesis in gene therapy and stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Gene therapy insertional mutagenesis insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Gene therapy: therapeutic gene causing lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Gene therapy: X-SCID transgene leukaemogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Transcription start regions in the human genome are favored targets for MLV integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Virology. Picking the right spot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Retroviral DNA integration: viral and cellular determinants of target-site selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Gene expression profile of murine long-term reconstituting vs. short-term reconstituting hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Pois(s)on--it's a question of dose...

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

7 January 2021

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

7 January 2021

Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

7 January 2021

Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

7 January 2021

Gene therapy: is IL2RG oncogenic in T-cell development?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

7 January 2021

Murine leukemia induced by retroviral gene marking

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

7 January 2021

Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.219

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.219

1 reference

19 August 2017

1 reference